Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
Major pharma trade organizations issued statements on December 25 following the Japanese government’s decision to push ahead with an “off-year” drug price revision in FY2025, with US and European groups harshly criticizing it as a reversal of pro-innovation policies. The…
To read the full story
Related Article
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
ORGANIZATION
- JETRO Opens 2026 Applications for Regenerative Medicine Program
July 2, 2026
- Incubator Led by Ex-Chugai CEO to Seek Govt Support, Raise Private Funds
June 30, 2026
- EFPIA Urges Global-Level Launch Prices, Patent-Term Price Protection
June 26, 2026
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…